

1
2
3
4
5
6

Risk prediction tools for pressure injury occurrence: An umbrella review of systematic reviews reporting model development and validation methods

7 Bethany Hillier^{1,2}
8 Katie Scandrett¹
9 April Coombe^{1,2}
10 Tina Hernandez-Boussard³
11 Ewout Steyerberg⁴
12 Yemisi Takwoingi^{1,2}
13 Vladica Velickovic^{5,6}
14 Jacqueline Dinnes^{1,2*}

15
16

Affiliations

18 ¹ Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham,
19 Edgbaston, Birmingham, UK

20 ² NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation
21 Trust and University of Birmingham, Birmingham, UK

22 ³ Department of Medicine, Stanford University, Stanford, CA USA

23 ⁴ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The
24 Netherlands

25 ⁵ Evidence Generation Department, HARTMANN GROUP, Heidenheim, Germany

26 ⁶ Institute of Public Health, Medical, Decision Making and Health Technology Assessment, UMIT, Hall,
27 Tirol, Austria

Email addresses

29 b.hillier@bham.ac.uk (BH); k.e.scandrett@bham.ac.uk (KS); a.r.coombe@bham.ac.uk (AC);
30 boussard@stanford.edu (THB); e.w.steyerberg@lumc.nl (ES); y.takwoingi@bham.ac.uk (YT);
31 vladica.velickovic@hartmann.info (VV)

32 * Corresponding author: j.dinnes@bham.ac.uk (JD)

Keywords

34 Development, internal, external validation, prediction, prognostic, pressure injury, ulcer, overview

35 ABSTRACT

36 Background

37 Pressure injuries (PIs) place a substantial burden on healthcare systems worldwide. Risk stratification
38 of those who are at risk of developing PIs allows preventive interventions to be focused on patients
39 who are at the highest risk. The considerable number of risk assessment scales and prediction
40 models available underscore the need for a thorough evaluation of their development, validation
41 and clinical utility.

42 Our objectives were to identify and describe available risk prediction tools for PI occurrence, their
43 content and development and validation methods used.

44 Methods

45 The umbrella review was conducted according to Cochrane guidance. MEDLINE, Embase, CINAHL,
46 EPISTEMONIKOS, Google Scholar and reference lists were searched to identify relevant systematic
47 reviews. Risk of bias was assessed using adapted AMSTAR-2 criteria. Results were described
48 narratively. All included reviews contributed to build a comprehensive list of risk prediction tools.

49 Results

50 We identified 32 eligible systematic reviews only seven of which described the development and
51 validation of risk prediction tools for PI. Nineteen reviews assessed the prognostic accuracy of the
52 tools and 11 assessed clinical effectiveness. Of the seven reviews reporting model development and
53 validation, six included only machine learning models. Two reviews included external validations of
54 models, although only one review reported any details on external validation methods or results.
55 This was also the only review to report measures of both discrimination and calibration. Five reviews
56 presented measures of discrimination, such as area under the curve (AUC), sensitivities, specificities,
57 F1 scores and G-means. For the four reviews that assessed risk of bias assessment using the
58 PROBAST tool, all models but one were found to be at high or unclear risk of bias.

59 Conclusions

60 Available tools do not meet current standards for the development or reporting of risk prediction
61 models. The majority of tools have not been externally validated. Standardised and rigorous
62 approaches to risk prediction model development and validation are needed.

63 Registration

64 The protocol was registered on the Open Science Framework (<https://osf.io/tepyk>).

65

66

67 INTRODUCTION

68 Pressure injuries (PI) carry a significant healthcare burden. A recent meta-analysis estimated the
69 global burden of PIs to be 13%, two-thirds of which are hospital-acquired PIs (HAPI).¹ The average
70 cost of a HAPI has been estimated as \$11k per patient, totalling at least \$27 billion a year in the
71 United States based on 2.5 million reported cases.² Length of hospital stay is a large contributing
72 cost, with patients over the age of 75 who develop HAPI having on average a 10-day longer hospital
73 stay compared to those without PI.³

74 PIs result from prolonged pressure, typically on bony areas like heels, ankles, and the coccyx, and are
75 more common in those with limited mobility, including those who are bedridden or wheelchair
76 users. PIs can develop rapidly, and pose a threat in community, hospital and long-term care settings.
77 Multicomponent preventive strategies are needed to reduce PI incidence⁴ with timely
78 implementation to both reduce harm and burden to healthcare systems.⁵ Where preventive
79 measures fail or are not introduced in adequate time, PI treatment involves cleansing, debridement,
80 topical and biophysical agents, biofilms, growth factors and dressings^{6,7,8}, and in severe cases, surgery
81 may be necessary.^{5,9}

82 A number of clinical assessment scales for assessing the risk of PI are available (e.g. Braden^{10,11},
83 Norton¹², Waterlow¹³) but are limited by reliance on subjective clinical judgment. Statistical risk
84 prediction models may offer improved accuracy over clinical assessment scales, however appropriate
85 methods of development and validation are required.^{14,15,16} Although methods for developing risk
86 prediction models have developed considerably,^{14,15,17,18} methodological standards of available
87 models have been shown to remain relatively low.^{17,19-22} Machine learning (ML) algorithms to
88 develop prediction models are increasingly commonplace, but these models are at similarly high risk
89 of bias²³ and do not necessarily offer any model performance benefit over the use of statistical
90 methods such as logistic regression.²⁴ Methods for systematic reviews of risk prediction model
91 studies have also improved,²⁵⁻²⁷ with tools such as PROBAST (Prediction model Risk of Bias
92 Assessment Tool)²⁸ now available to allow critical evaluation of study methods.

93 Although several systematic reviews of PI risk assessment scales and risk prediction models for PI
94 (subsequently referred to as risk prediction tools) are available²⁹⁻³⁸, these have been demonstrated to
95 frequently focus on single or small numbers of scales or models, use variable review methods and
96 show a lack of consensus about the accuracy and clinical effectiveness of available tools.³⁹ We
97 conducted an umbrella review of systematic reviews of risk prediction tools for PI to gain further
98 insight into the methods used for tool development and validation, and to summarise the content of
99 available tools.

100 METHODS

101 Protocol registration and reporting of findings

102 We followed guidance for conducting umbrella reviews provided in the Cochrane Handbook for
103 Intervention Reviews.⁴⁰ The review was reported in accordance with guidelines for Preferred
104 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)⁴¹ (see Appendix 1), adapted for
105 risk prediction model reviews as required. The protocol was registered on the Open Science
106 Framework (<https://osf.io/tepyk>).

107 Literature search

108 Electronic searches of MEDLINE, Embase via Ovid and CINAHL Plus EBSCO from inception to June
109 2024 were developed, tested and conducted by an experienced information specialist (AC),

110 employing well-established systematic review and prognostic search filters⁴²⁻⁴⁴ combined with
111 specific keyword and controlled vocabulary terms relating to PIs. Additional simplified searches were
112 undertaken in EPISTEMONIKOS and Google Scholar due to the more limited search functionality of
113 these two sources. The reference lists of all publications reporting reviews of prediction tools
114 (systematic or non-systematic) were reviewed to identify additional eligible systematic reviews and
115 to populate a list of PI risk prediction tools. Title and abstract screening and full text screening were
116 conducted independently and in duplicate by two of four reviewers (BH, JD, YT, KS). Any
117 disagreements were resolved by discussion or referral to a third reviewer.

118 Eligibility criteria for this umbrella review

119 Published English-language systematic reviews of risk prediction models developed for adult patients
120 at risk of PI in any setting were included. Reviews of clinical risk assessment tools or models
121 developed using statistical or ML methods were included, both with or without internal or external
122 validation. The use of any PI classification system^{6 45-47} as a reference standard was eligible. Reviews
123 of the diagnosis or staging of those with suspected or existing PIs or chronic wounds, reviews of
124 prognostic factor and predictor finding studies, and models exclusively using pressure sensor data
125 were excluded.

126 Systematic reviews were required to report a comprehensive search of at least two electronic
127 databases, and at least one other indicator of systematic methods (i.e. explicit eligibility criteria,
128 formal quality assessment of included studies, sufficient data presented to allow results to be
129 reproduced, or review stages (e.g. search screening) conducted independently in duplicate).

130 Data extraction and quality assessment

131 Data extraction forms (Appendix 3) were developed using the CHARMS checklist (ChEcklist for critical
132 Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) and Cochrane
133 Prognosis group template.^{48 49} One reviewer extracted data concerning: review characteristics, model
134 details, number of studies and participants, study quality and results. Extractions were
135 independently checked by a second reviewer. Where discrepancies in model or primary study details
136 were noted between reviews, we accessed the primary model development publications where
137 possible.

138 The methodological quality of included systematic reviews was assessed using AMSTAR-2 (A
139 Measurement Tool to Assess Systematic Reviews)⁵⁰, adapted for systematic reviews of risk prediction
140 models (Appendix 4). Quality assessment and data extraction were conducted by one reviewer and
141 checked by a second (BH, JD, KS), with disagreements resolved by consensus. Our adapted AMSTAR-2
142 contains six critical items, and limitations in any of these items reduce the overall validity of a
143 review.⁵⁰

144 Synthesis methods

145 Reviews were considered according to whether any information concerning model development and
146 validation was reported. This specifically refers to reporting methods of model development or
147 validation, and/or the presentation of measures of both discrimination and calibration. This is in
148 contrast to evaluations of prognostic accuracy, where models are applied at a binary threshold (e.g.,
149 for high or low risk), and present only discrimination metrics with no further consideration of model
150 performance. Available data were tabulated, and a narrative synthesis provided.

151 All risk prediction models identified are listed in Appendix 5 Table S4, including those for which no
152 information about model development or validation was provided at systematic review level. Risk
153 prediction models were classified as ML-based or non-ML models, based on how they were classified

154 in included systematic reviews, including cases where models such as logistic regression were treated
155 as ML-based models. Where possible, the predictors included in the tools were extracted at review
156 level and categorised into relevant groups in order to describe the candidate predictors associated
157 with risk of PI. No statistical synthesis of systematic review results was conducted.

158 Reviews reporting results as prognostic accuracy (i.e. risk classification according to a binary decision)
159 or clinical effectiveness (i.e. impact on patient management and outcomes) are reported
160 elsewhere.³⁹ Hereafter, the term clinical utility is used to encompass both accuracy and clinical
161 effectiveness.

162 RESULTS

163 Characteristics of included reviews

164 Following de-duplication of search results, 7200 unique records remained, of which 118 were
165 selected for full text assessment. We obtained the full text of 111 publications of which 32 met all
166 eligibility criteria for inclusion (see Figure 1). Seven reviews reported details about model
167 development and internal validation^{36 37 51-55}, two of which also considered external validation^{52 54}; 19
168 reported accuracy data^{29 31-35 38 54 56-66}, and 11 reported clinical effectiveness data.^{30 56 58 61 66-72} One
169 review⁵⁴ reported both model development and accuracy data, and four reviews reported both
170 accuracy and effectiveness data.^{56 58 61 66}

171 Table 1 provides a summary of systematic review methods for all 32 reviews according to whether or
172 not they reported any tool development methods (see Appendix 5 for full details). The seven reviews
173 reporting prediction tool development and validation were all published within the last six years
174 (2019 to 2024) compared to reviews focused on the clinical utility of available tools (published from
175 2006 to 2024). Reviews focused on model development methods almost exclusively focused on ML-
176 based models (all but one⁶⁰ of the seven reviews limited inclusion to ML models), and frequently did
177 not report study eligibility criteria related to study participants or setting (Table 1). In comparison,
178 only two reviews (8%) concerning the clinical utility of models included ML-based models,^{38 54} but
179 more often reported eligibility criteria for population or setting: hospital settings (n = 3),^{33 38 54} or
180 surgical settings (n=8),^{34 61 63 64 70 31} hospital or acute settings (n=2)^{67 71}, long-term care settings
181 (n=2)^{29 35} or the elderly (n=1).⁶⁰


182 On average, reviews about tool development included more studies than reviews of clinical utility
183 (median 22 compared to 15), more participants (median 408,504 compared to 7,684) and covered
184 more prediction tools (median 21 compared to 3) (Table 1). Ten reviews (38%) about clinical utility
185 included only one risk assessment scale, whereas reviews of tool development included at least 3
186 different risk prediction models. The PROBAST tool for quality assessment of prediction model
187 studies was used in 57% (n=4) of tool development reviews^{37 52-54}, whereas validated test-accuracy
188 specific tools such as QUADAS were used less frequently (10/26, 38%) in reviews of clinical utility.
189 Two reviews of tool development did not report any quality assessment of included studies (29%),
190 compared to 4 (15%) of reviews of clinical utility. Meta-analysis was conducted in two of seven (29%)
191 reviews of tool development compared to more than half of reviews of clinical utility (15, 58%).

192 Methodological quality of included reviews

193 The quality of included reviews was generally low (Table 2; Appendix 5 for full assessments). The
194 majority of reviews (71% (5/7) reviews on tool development and 78% (18/23) reviews on clinical
195 utility) partially met the AMSTAR-2 criteria for the literature search (i.e. searched two databases,
196 reported search strategy or key words, and justified language/publication restrictions), with only
197 three (two reviews^{56 72} on clinical utility, and one review⁵⁴ on both tool development and clinical


198 utility) meeting all criteria for ‘Yes’ (i.e. searching grey literature and reference lists, with the search
199 conducted within 2 years of publication). Twenty-two reviews (69%) conducted study selection in
200 duplicate (5/7 (71%) of reviews about tool development and 17/26 (65%) of clinical utility reviews).
201 Conflicts of interest were reported in all seven tool development reviews and 77% of clinical utility
202 reviews (20/26). Reviews scored poorly on the remaining AMSTAR-2 items, with around 50% or fewer
203 reviews meeting the stipulated AMSTAR-2 criteria. Nine reviews (28%) used an appropriate method
204 of quality assessment of included studies and provided itemisation of judgements per study. No
205 review scored ‘Yes’ for all AMSTAR-2 items in either category.

206 *Figure 1. PRISMA⁴¹ flowchart: identification, screening and selection process*



207 *List of full-text articles excluded, with reasons, is given in Appendix 5. *Note that one review⁵⁴ is included in both.*

Table 2. Summary of AMSTAR-2 assessment results



AMSTAR – A MeaSurement Tool to Assess systematic Reviews; Item 1 – Adequate research question/ inclusion criteria?; Item 2 – Protocol and justifications for deviations?; Item 3 – Reasons for study design inclusions?; Item 4 – Comprehensive search strategy?; Item 5 – Study selection in duplicate?; Item 6 – Data extraction in duplicate?; Item 7 – Excluded studies list (with justifications?); Item 8 – Included studies description adequate?; Item 9 – Assessment of RoB/quality satisfactory?; Item 10 – Studies’ sources of funding reported?; Item 11 – Appropriate statistical synthesis method?; Item 12 – Assessment of impact of RoB on synthesised results?; Item 13 – Assessment of impact of RoB on review results?; Item 14 – Discussion/investigation of heterogeneity?; Item 15 – Conflicts of interest reported?; N/A – not applicable; RoB – risk of bias. Further details on AMSTAR items are given in Appendix 4, and results per review are given in Appendix 5. Note that where AMSTAR-2 assessment was applied to overlapping reviews (n=3) for prognostic accuracy and clinical effectiveness separately, and resulted in differing judgements for each review question, the judgements for the prognostic accuracy review question are displayed here for simplicity.

209 Findings

210 Of the 32 reviews, 26 reviews focused on the clinical utility (accuracy or effectiveness) of prediction
211 tools. These clinical utility reviews provided no details about the development or validation of
212 included models (except for one review⁵⁴), and gave only limited detail about setting and study
213 design (see Appendix 5). Reviews reporting the accuracy of prediction tools largely treated the tools
214 as diagnostic tests to be applied at a single threshold (e.g., for high or low risk) and they did not focus
215 on the broader aspects of prognostic model performance, such as calibration and the temporal
216 relationship between prediction and the outcome, PI occurrence. These reviews included a total of
217 70 different prediction tools, predominantly derived by clinical experts, as opposed to empirically-
218 derived models (that is, with statistical or ML methods). The methodology underlying their
219 development is not always explicit, with scales in routine clinical usage apparently based on
220 epidemiological evidence and clinical judgment about predictors that may not meet accepted
221 principles for the development and reporting of risk prediction models. The most commonly
222 included tools were the Braden^{10 11} (included in 21 reviews), Waterlow¹³ (n=14 reviews), Norton¹²
223 (n=11 reviews), and Cubbin and Jackson scales^{97 98} (n=8 reviews).

224 The seven systematic reviews that reported detailed information about model development and
225 validation included 70 prediction models, 48 of which were unique to these seven reviews. Between
226 three⁵¹ and 35³⁶ model development studies were included; one review⁵² also included eight external
227 validation studies and another review⁵⁴ included one external validation study. Electronic health
228 records (EHRs) were used for model development in all studies in one review³⁷ and for the majority
229 of models (>66%) in the remaining reviews, where reported.^{51 54 55 53} Three reviews^{52 54 55} reported the
230 use of prospectively or retrospectively collected data. No review included information about the
231 thresholds used to define whether a patient is at risk of developing PIs. Five reviews included detail
232 about the predictors included in each model.

233 The largest review³⁶ reported that logistic regression was the most commonly reported modelling
234 approach (20/35 models), followed by random forest (n=18), decision tree (n=12) and support vector
235 machine (n=12) approaches. Logistic regression was also the most frequently used approach in three
236 other reviews (18/23⁵⁵, 16/21⁵² and 15/22⁵³). Primary studies frequently compared the use of
237 different ML methods using the same datasets, such that 'other' ML methods were reported with
238 little to no further detail (e.g. 19 studies in the review by Dweekat and colleagues³⁶).

239 Approaches to internal validation were not well reported in the primary studies. One review⁵² found
240 no information on internal validation for 76% (16/21) of studies; with re-sampling reported in two
241 and tree-pruning, cross-validation and split sample reported in one study each. Another review³⁶
242 reported finding no information about internal validation for 20% of studies (7/35) and the use of
243 cross-validation (n=10), split sample (n=10) techniques, or both (n=8) for the remainder. Cross-
244 validation was used in more than half (12/22) of studies in another.⁵³

245 Only one review reported details on methods for selection of model predictors⁵²: 29% (6/21)
246 selected predictors by univariate analysis prior to modelling and 9 used stepwise selection for final
247 model predictors; 11 (52%) clearly reported candidate predictors, and all 21 clearly reported final
248 model predictors. Another review⁵⁴ stated that feature selection (or predictor selection) was
249 performed improperly and that some studies used univariate analyses to select predictors, but
250 further details were not provided. One review⁵² reported 15 models (71%) with no information about
251 missing data, and only two using imputation techniques (imputation using another data set, and
252 multiple imputation by chained equations). Another review⁵⁴ reported 7 models (39%) with no

253 information about missing data, missing data excluded or negligible for 4 models (22%), and single or
254 multiple imputation techniques used for 5 (28%) and 3 (17%) models, respectively.

255 Model performance measures were reported by three reviews^{37 52 53}, all of which noted considerable
256 variation in reported metrics and model performance including C-statistics (0.71 to 0.89 in 10
257 studies⁵³), F1 score (0.02 to 0.99 in 9 studies⁵³), G-means (0.628 to 0.822 in four studies³⁷), and
258 observed versus expected ratios (0.97 to 1 in 3 studies⁵²). Four reviews^{37 53-55} reported measures of
259 discrimination associated with included models. Across reviews, reported sensitivities ranged
260 between 0.04 and 1, specificities ranged between 0.69 and 1, and AUC values ranged between 0.50
261 and 1.

262 Shi and colleagues⁵² included eight external validations using data from long-term care (n=4) or acute
263 hospital care (n=4) settings (Appendix 5 Table S5). All were judged to be at unclear (n=4) or high
264 (n=4) risk of bias using PROBAST. Model performance metrics for five models (TNH-PUPP⁸⁹, Berlowitz
265 11-item model⁹⁹, Berlowitz MDS adjustment model⁹⁰, interRAI PURS⁸⁸, Compton ICU model⁹⁴)
266 included C-statistics between 0.61 and 0.9 and reported observed versus expected ratios were
267 between 0.91 and 0.97. The review also reported external validation studies for the 'SS scale'¹⁰⁰ and
268 the prePURSE study tool⁹¹, but no model performance metrics were given. A meta-analysis of C-
269 statistics and O/E ratios was performed, including values from both development and external
270 validation cohorts (Table 3). Parameters related to model development were not consistently
271 reported: C-statistics ranged between 0.71 and 0.89 (n = 10 studies); observed versus expected ratios
272 ranged between 0.97 and 1 (n=3 studies).

273 Pei and colleagues⁵⁴ reported that one⁸¹ (1/18, 6%) of the model development studies included in
274 their review also conducted an external validation. However, review authors presented accuracy
275 metrics that originated from the internal validation, as opposed to the external validation
276 (determined from inspection of the primary study). Additionally, no details on external validation
277 methods and no measures of calibration were presented. Pei and colleagues⁵⁴ judged this study to be
278 of high risk of bias using PROBAST, as with the majority of studies (16/18, 89%) included in their
279 review. More detailed information about individual models, including predictors, specific model
280 performance metrics and sample sizes, is presented in Appendix 5.

281 **Included tools and predictors**

282 A total of 124 risk prediction tools were identified (Table 4); 111 tools were identified from the 32
283 included systematic reviews and 13 were identified from screening the reference lists of literature
284 reviews that used non-systematic methods that were considered during full text assessment. Full
285 details obtained at review-level are reported in Appendix 5 Table S4.

286 Tools were categorised as having been developed with (60/124, 48%) or without (64/124, 52%) the
287 use of ML methods (as defined by review authors). Prospectively collected data was used for model
288 development for 21% of tools (26/124), retrospectively collected data for 41% (51/124), or was not
289 reported (47/124). Information about the study populations was poorly reported, however study
290 setting was reported for 112 prediction tools. Twenty-seven tools were reported to have been
291 developed in hospital inpatients, and 22 were developed in long-term care settings, rehabilitation
292 units or nursing homes or hospices. Where reported (n=100), sample sizes ranged from 15¹⁰¹ to
293 1,252,313.¹⁰² The approach to internal validation used for the prediction tools (e.g. cross-validation
294 or split sample) was not reported at review-level for over two thirds of tools (83/124, 67%).

295 We could extract information about the predictors for only 66 of the 124 tools (Table 5 and Appendix
296 5). The most frequently included predictor was age (33/66, 50%), followed by pre-disposing

297 diseases/conditions (32/66, 48%), medical treatment/care received (28/66, 42%) and mobility
298 (27/66, 41%). Tools often (31/66, 47%) included multiple pre-existing conditions or comorbidities
299 and multiple types of treatment or medication as predictors. Other common predictors include
300 laboratory values, continence, nutrition, body-related values (e.g. weight, height, body temperature),
301 mental status, activity, gender and skin assessment (27% to 35% of tools). Ten tools incorporated
302 scores from other established risk prediction scales as a predictor, with eight including Braden^{10 11}
303 scores, one including the Norton¹² score and one including the Waterlow¹³ score.

304 Only one review⁵² reported the presentation format of included tools, coded as 'score system'
305 (n=11), 'formula equation' (n=3), 'nomogram scale' (n=2), or 'not reported' (n=6).

306

307 Table 4. Summary of tool characteristics, extracted at review-level

Tool characteristics	ML-based models (N=60, 48%)	Non-ML tools (N=64, 52%)	Total (N=124)
No. of included reviews^A considered in			
0	0 (0)	13 (20)	13 (10)
1	31 (52)	23 (36)	54 (44)
2	6 (10)	9 (14)	15 (12)
>2	23 (38)	19 (30)	42 (34)
Development study details			
Median (range) year of publication	2020 (2000 – 2023)	1998 (1962 – 2015)	2008 (1962 – 2023)
Source of data			
Prospective	8 (13)	18 (28)	26 (21)
Retrospective	41 (68)	10 (16)	51 (41)
NS	11 (18)	36 (56)	47 (38)
Setting			
Hospital	16 (27)	11 (17)	27 (22)
Long-term care (incl. end-of-life and rehab)	8 (13)	14 (22)	22 (18)
Acute care (incl. surgical and ICU)	33 (55)	24 (38)	57 (46)
Mixed settings	1 (2)	1 (2)	2 (2)
Other	2 (3)	2 (3)	4 (3)
NS	0 (0)	12 (19)	12 (10)
Study population age			
Adults	36 (60)	34 (53)	70 (56)
Any	4 (7)	3 (5)	7 (6)
NS	20 (33)	27 (42)	47 (38)
Baseline condition			
PIs at baseline	1 (2)	0 (0)	1 (1)
No PIs at baseline	11 (18)	19 (30)	30 (24)
NS	48 (80)	45 (70)	93 (75)
Development methods			
Development method/algorithm^B			
ML algorithms	48 (80)	0 (0)	48 (39)
Logistic regression	40 (67)	15 (23) ^C	55 (44)
Cox regression	0 (0)	5 (8)	5 (4)
Fine-Gray model	2 (3)	0 (0)	2 (2)
Clinical expertise	0 (0)	2 (3)	2 (2)
NS	0 (0)	44 (69) ^D	44 (35)
Internal validation method^B			
Cross-validation	21 (35)	3 (5) ^G	24 (19)
Data splitting	28 (47)	0 (0)	28 (23)
Not done / NS	22 (37) ^H	61 (95)	83 (67)
Median (range) no. of final predictors^E	7 (3 – 23)	8 (3 – 12)	7 (3 – 23)
Study cohort			
Median (range) total sample size	2674 (27 – 1252313)	285 (15 – 31150)	686 (15 – 1252313)
Median (range) number of events	207 (8 – 86410)	51 (9 – 1350)	98 (8 – 86410)
Median (range) proportion of events (% of sample size)	10.43% (0.42% – 80.00%)	14.84% (1.18% – 46.67%)	14.69% (0.42% – 80.00%)

308 Note that tools were categorised as ML or non-ML tools based on the descriptions from authors of the included systematic
 309 reviews that the tools were identified in. ^A the 32 included systematic reviews; ^B tools use multiple methods, therefore total
 310 number not equal to N (100%); ^C one study also used discriminant analysis for model development; ^D many seemed to use
 311 clinical expertise, but development methods were not clearly reported; ^E counting of final predictors may vary between
 312 models: some authors may count individual factors, while others consider domains or subscales; ^F one review³⁶ implies 5
 313 models did not implement internal validation; ^G 'resampling' (not described further) was used for the development of 2
 314 models; ML – machine learning; NS – not stated; ICU – intensive care unit; PI – pressure injury.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

315

Table 5. Predictor categories and frequency (%) of inclusion in N=66 tools.

Predictor category	No. of tools predictor appears in
Age	33 (50)
Pre-disposing conditions	32 (48)
Receiving medical treatment/care	28 (42)
Mobility	27 (41)
Laboratory values	23 (35)
Continence	22 (33)
Nutrition	22 (33)
Body	21 (32)
Mental Status	21 (32)
Activity	21 (32)
Gender	21 (32)
Skin	18 (27)
General Health	14 (21)
Braden ^{10,11} score	8 (12)
Length of stay	8 (12)
Pressure injury	7 (11)
Surgery duration	6 (9)
Ability to ambulate	6 (9)
Medical unit, ward, visit	5 (8)
Ethnicity or place of birth	5 (8)
Friction, shear, pressure	3 (5)
Body position	3 (5)
Pain	3 (5)
Hygiene	2 (3)
Isolation	2 (3)
Smoking	2 (3)
Norton ¹² or Waterlow ¹³ score	2 (3)
'Special' (not explained)	2 (3)

316

Figures are given as count (% out of 66 tools with information on predictors). Note that multiple predictors may fall within the same predictor category. For instance, the category 'skin' may encompass both 'skin moisture' and 'skin integrity', with the frequency count reflecting the entire predictor category rather than individual predictors.

317

318

319

320 DISCUSSION

321 This umbrella review summarises data from 32 eligible systematic reviews of PI risk prediction tools.
322 Quality assessment using an adaptation of AMSTAR-2 revealed that most reviews were conducted to
323 a relatively poor standard. Critical flaws were identified, including inadequate or absent reporting of
324 protocols (23/32, 72%), inappropriate statistical synthesis methods (13/17, 76%) and lack of
325 consideration for risk of bias judgements when discussing review results (17/32, 53%). Despite the
326 large number of risk prediction models identified, only seven reviews reported information about
327 model development and validation, predominantly for ML-based prediction models. The remaining
328 reviews reported the accuracy (sensitivity and specificity), or effectiveness of identified models. The
329 studies included in the ‘accuracy’ reviews that we identified, typically reported a binary classification
330 of participants as high or low risk of PI based on the risk prediction tool scores, rather than
331 constituting external validations of models. For many (44/64, 69%) prediction tools that were
332 developed without the use of ML, we were not able to determine whether reliable and robust
333 statistical methods were used or whether models were essentially risk assessment tools developed
334 based on expert knowledge. For nearly half (58/124, 47%) of the identified tools, predictors included
335 in the final models were not reported. Details of study populations and settings were also lacking. It
336 was not always clear from the reviews whether the poor reporting occurred at review level or in the
337 original primary study publications.

338 Model development algorithms included logistic regression, decision trees and random forests, with
339 a vast number of ML-based models having been developed in the last five years. Although logistic
340 regression is considered a statistical approach¹⁰⁷, it does share some characteristics with ML
341 methods.¹⁰⁸ Modern ML frameworks and libraries have streamlined the automation of logistic
342 regression, including feature selection, hyperparameter optimisation, and cross-validation, solidifying
343 its role within the ML ecosystem; however, logistic regression may still appear in non-ML contexts, as
344 some developers continue to apply it using more traditional methods. Most (6/7, 86%) of our set of
345 reviews reported the use of logistic regression as part of an ML-based approach, however this
346 reflects the classifications used by included systematic reviews as opposed to our own assessment of
347 the methods used in the primary studies, and may therefore be an overestimation of the use of ML
348 models.

349 In contrast to logistic regression approaches, decision trees and random forests may not produce a
350 quantitative risk probability. Instead, they commonly categorise patients into binary ‘at risk’ or ‘not
351 at risk’ groups. Although the risk probabilities generated in logistic regression prediction models can
352 be useful for clinical decision making, it was not possible to derive any information about thresholds
353 used to define ‘at risk’ or ‘not at risk’, and for most reviews, it was unclear what the final model
354 comprised of. This lack of transparency poses potential hurdles in applying these models effectively
355 in clinical settings.

356 A recent systematic review of risk of bias in ML-developed prediction models found that most
357 models are of poor methodological quality and are at high risk of bias.²³ In our set of reviews, of the
358 four reviews that conducted a risk of bias assessment using the PROBAST tool, all models but one¹⁰³
359 were found to be at high or unclear risk of bias.^{37 52-54} This raises significant concerns about the
360 accuracy of clinical risk predictions. This issue is particularly critical in light of emerging evidence¹⁰⁴
361 on skin tone classification versus ethnicity/race-based methods in predicting pressure ulcer risk.
362 These results underscore the need for developing bias-free predictive models to ensure accurate and
363 equitable healthcare outcomes, especially in diverse patient populations.

364 Where the method of internal validation was reported, split-sample and cross-validation were the
365 most commonly used techniques, however, detail was limited, and it was not possible to determine
366 whether appropriate methods had been used. Although split-sample approaches have been favoured
367 for model validation, more recent empirical work suggests that bootstrap-based optimism
368 correction¹⁰⁵ or cross-validation¹⁰⁶ are preferred approaches. None of the included reviews reported
369 the use of optimism correction approaches.

370 Only two reviews included external validations of previously developed models^{52 54}, however limited
371 details of model performance were presented. External validation is necessary to ensure a model is
372 both reproducible and generalisable^{109 110}, bringing the usefulness of the models included in these
373 reviews into question. The PROGRESS framework suggests that multiple external validation studies
374 should be conducted using independent datasets from different locations.¹⁵ In the two reviews that
375 included model validation studies^{52 54}, it is unclear whether these studies were conducted in different
376 locations. Where reported, they were all conducted in the same setting as the corresponding
377 development study. PROGRESS also suggests that external validations are carried out in a variety of
378 relevant settings. Shi and colleagues⁵² described four of eight validations as using ‘temporal’ data,
379 which suggests that the validation population is largely the same as the development population but
380 with use of data from different timeframes. This approach has been described as lying somewhere
381 ‘between’ internal and external validation, further emphasising the need for well-designed external
382 validation studies.¹⁰⁹

383 Importantly, model recalibration was not reported for any external validations. Evidence suggests
384 greater focus should be placed on large, well-designed external validation studies to validate and
385 improve promising models (using recalibration and updating¹¹¹), rather than developing a multitude
386 of new ones.^{15 18} Model validation and recalibration should be a continuous process, and this is
387 something that future research should address. Following external validation, effectiveness studies
388 should be conducted to assess the impact of model use on decision making, patient outcomes and
389 costs.¹⁵

390 The effective use of prediction tools is also influenced by the way in which the model’s output is
391 presented to the end-user. Only one review⁵² reported the presentation format of included tools,
392 such as formula equations and nomograms. In conjunction with this, identifying and mitigating
393 modifiable risk factors can help prevent PIs. Additional effort is needed in the development of risk
394 prediction tools to extract predictors that are risk modifiers and provide end-users with this
395 information, to make the predictions more interpretable and actionable.

396 Risk stratification in itself is not clinically useful unless it leads to an effective change in patient
397 management. For instance, in high-risk groups, additional types of preventive interventions can be
398 triggered, or default preventive measures can be applied more intensively (e.g., more frequent
399 repositioning) based on the results of the risk assessment. While sensitivity and specificity are valid
400 performance metrics, their optimisation must consider the cost of misclassification. Net benefit
401 calculations, which can be visualised through decision curves,¹¹² provide a more reliable means of
402 evaluating the clinical utility of risk assessment for PIs across a range of thresholds at which clinical
403 action is indicated. These calculations can assist in providing a balanced use of resources while
404 maximising positive health outcomes, such as lowering incidence of PI.

405 It is also important to assess whether the tool can improve outcomes with existing preventive
406 interventions and whether it integrates well into clinical workflows (i.e., clinical effectiveness). A
407 well-developed tool with good calibration and discrimination properties may be of limited value if
408 these practical concerns are not addressed. Therefore, model developers should check the expected

409 value of prognosis and how the tool can guide prevention when employed in practice, before
410 planning model development. If it's determined that there is no value in predicting certain outcomes
411 – that brings into question whether the model should even be developed.¹¹³

412 Despite the advances in methods for developing risk prediction models, scales developed using
413 clinical expertise such as the Braden Scale^{10,11}, Norton Scale¹², Waterlow Score¹³ and Cubbin-Jackson
414 Scales^{97,98} are extensively discussed in numerous clinical practice guidelines for patient risk
415 assessment, and are commonly used in clinical practice.^{6,114} Although guidelines recognise their low
416 accuracy, they are still acknowledged, while other risk prediction models are not even considered.
417 This may be due to the availability of at least some clinical trials evaluating the clinical utility of
418 scales.³⁹ Some scales, such as the Braden scale^{10,11}, are so widely used that they have become an
419 integral component of risk assessment for PI in clinical practice, and have even been incorporated
420 into EHRs. Their widespread use may impede the progress towards development, validation and
421 evaluation of more accurate and innovative risk prediction models. Striking a balance between
422 tradition and embracing advancements is crucial for effective implementation in healthcare settings
423 and improving patient outcomes.

424 Strengths and limitations

425 Our umbrella review is the first to systematically identify and evaluate systematic reviews of risk
426 prediction models for PI. The review was conducted to a high standard, following Cochrane
427 guidance⁴⁰, and with a highly sensitive search strategy designed by an experienced information
428 specialist. Although we excluded non-English publications due to time and resource constraints,
429 where possible these publications were used to identify additional eligible risk prediction models. To
430 some extent our review is limited by the use of AMSTAR-2 for quality assessment of included
431 reviews. AMSTAR-2 was not designed for assessment of diagnostic or prognostic studies and,
432 although we made some adaptations, many of the existing and amended criteria relate to the quality
433 of reporting of the reviews as opposed to methodological quality. There is scope for further work to
434 establish criteria for assessing systematic reviews of prediction models.

435 The main limitation, however, was the lack of detail about risk prediction models and risk prediction
436 model performance that could be determined from the included systematic reviews. To be as
437 comprehensive as possible in model identification, we were relatively generous in our definition of
438 'systematic', and this may have contributed to the often-poor level of detail provided by included
439 reviews. It is likely, however, that reporting was poor in many of the primary studies contributing to
440 these reviews. Excluding the ML-based models, more than half of available risk prediction scales or
441 tools were published prior to the year 2000. The fact that the original versions of reporting
442 guidelines for diagnostic accuracy studies¹¹⁵ and risk prediction models¹¹⁶ were not published until
443 2003 and 2015 respectively, is likely to have contributed to poor reporting. In contrast, the ML-based
444 models were published between 2000 and 2023, with a median year of 2020. Reporting guidelines
445 for development and validation of ML-based models are more recent^{117,118}, but aim to improve the
446 reporting standards and understanding of evolving ML technologies in healthcare.

447 CONCLUSIONS

448 There is a very large body of evidence reporting various risk prediction scales, tool and models for PI
449 which has been summarised across multiple systematic reviews of varying methodological quality.
450 Only five systematic reviews reported the development and validation of models to predict risk of
451 PIs. It seems that for the most part, available models do not meet current standards for the
452 development or reporting of risk prediction models. Furthermore, most available models, including
453 ML-based models have not been validated beyond the original population in which they were

454 developed. Identification of the optimal risk prediction model for PI from those currently available
455 would require a high-quality systematic review of the primary literature, ideally limited to studies
456 conducted to a high methodological standard. It is evident from our findings that there is still a lack
457 of consensus on the optimal risk prediction model for PI, highlighting the need for more standardised
458 and rigorous approaches in future research.

459

460 Table 1. Summary of included systematic review characteristics

Review characteristics	Reviews on model development and validation (N=7)	Reviews on accuracy or clinical effectiveness (N=26)	All included reviews (N=32)
Median (range) year of publication	2022 (2019 – 2023)	2017 (2006 – 2024)	2019 (2006 – 2024)
Eligibility criteria			
Participants			
Adults only	2 (29) ^A	15 (58) ^B	16 (50) ^{A,B}
Any age	0 (0)	2 (8)	2 (6)
No age restriction reported	5 (71)	9 (35)	14 (44)
Presence of PI at baseline			
No PIs at baseline	0 (0)	6 (23)	6 (19)
NS	7 (100)	20 (77)	26 (81)
Setting			
Any healthcare setting	0 (0)	2 (8)	2 (6)
Hospital	3 (43)	3 (12)	5 (16)
Acute care (incl. surgical and ICU)	0 (0)	8 (31)	8 (25)
Hospital or acute care	0 (0)	2 (8)	2 (6)
Long-term care	0 (0)	2 (8)	2 (6)
Long-term, acute or community settings	0 (0)	1 (4)	1 (3)
NS	4 (57)	8 (31)	12 (38)
Risk assessment tools			
Any prediction tool or scale	0 (0)	9 (35)	9 (28)
Specified clinical scale(s)	0 (0)	12 (46)	12 (38)
ML-based prediction models	6 (86)	2 (8)	7 (22)
ML or statistical models	1 (14)	0 (0)	1 (3)
PI prevention strategies	0 (0)	1 (4)	1 (3)
NS	0 (0)	2 (8)	2 (6)
PI classification system			
Any	0 (0)	1 (4)	1 (3)
Accepted standard classifications	0 (0)	2 (8)	2 (6)
Several specified classification systems (NPUAP, EPUAP, AHCPR or TDCPS)	0 (0)	3 (12)	3 (9)
Other	0 (0)	1 (4)	1 (3)
NS	7 (100)	19 (73)	25 (78)
Source of data			
Prospective only	0 (0)	4.5 (17) ^C	4.5 (14) ^C
Prospective or retrospective	1 (14)	2.5 (10) ^C	3.5 (41) ^C
NS	6 (86)	19 (73)	24 (75)
Study design restrictions			
Yes	1 (14)	14 (54)	15 (47)
No	0 (0)	3 (12)	3 (9)
NS	6 (86)	9 (35)	14 (44)
Review methods			
Median (range) no. sources^D searched	5 (2 – 9)	6 (2 – 14)	5 (2 – 14)
Publication restrictions:			
End date (year)			
2000-2009	0 (0)	3 (12)	3 (9)
2010-2019	1 (14)	16 (62)	17 (53)
2020-2023	6 (86)	7 (27)	12 (38)
Language			
English only	5 (71)	10 (38)	15 (47)
2 languages	1 (14)	3 (12)	3 (9)
>2 languages	0 (0)	3 (12)	3 (9)
No restrictions	0 (0)	4 (15)	4 (13)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

NS	1 (14)	6 (23)	7 (23)
Quality assessment tool^E			
PROBAST	4 (57)	1 (4) ^F	4 (13) ^F
QUADAS	0 (0)	2 (8)	2 (6)
QUADAS-2	0 (0)	8 (31)	8 (25)
JB I tools	1 (14)	3 (12)	4 (13)
CASP	0 (0)	2 (8)	2 (6)
Cochrane RoB tool	0 (0)	1 (4)	1 (3)
Other	0 (0)	6 (23)	6 (19)
None	2 (29)	4 (15)	6 (19)
Meta-analysis included	2 (29)	15 (58)	16 (50)
Method of meta-analysis (% of reviews incl. meta-analysis)			
Univariate RE/FE model (depending on heterogeneity assessment)	1 (50) ^G	2 (13) ^G	3 (19)
Univariate RE model	1 (50)	6 (40) ^G	6 (38) ^G
Hierarchical model (for DTA studies)	0 (0)	2 (13)	2 (13)
Unclear/NS	0 (0)	5 (33) ^G	5 (31) ^G
Volume of evidence			
Median (range) no. studies	22 (3 – 35)	15 (1 – 70)	17 (1 – 70)
Median (range) no. participants	408,504 (6,674 – 1,278,148)	7,684 (528 – 408,504)	11,729 (528 – 1,278,148)
Median (range) no. tools	21 (3 – 35)	3 (1 – 28)	4 (1 – 35)

461 Figures are number (%) of reviews, unless otherwise specified. ^A one review⁵⁵ specified restricting to “adult” populations,
 462 but only restricted by aged ≥14 years; ^B one review⁶⁰ restricted to aged >60 years; ^C one review⁵⁶ states either prospective
 463 or retrospective data eligible for Research Question 1, but prospective only for Research Question 2, hence 0.5 added to
 464 each category; ^D including databases, bibliographies or registries; ^E reviews may fall into multiple categories, therefore total
 465 number within domain not necessarily equal to N (100%); ^F one review³⁸ reported use of PROBAST in methods, but did not
 466 present any PROBAST results; ^G one review conducts univariate meta-analysis for a single estimate, e.g. c-statistic⁵², AUC⁶²,
 467 RR⁵⁷, or OR.⁵⁸

468 AHCPR – Agency for Health Care Policy and Research; CASP – Critical Appraisal Skills Programme; DTA – diagnostic test
 469 accuracy; EPUAP – European Pressure Ulcer Advisory Panel; FE – fixed effects; ICU – intensive care unit; JB I – Joanna Briggs
 470 Institute; ML – machine learning; NPUAP – National Pressure Ulcer Advisory Panel; NS – not stated; PI – pressure injury;
 471 PROBAST – Prediction model Risk of Bias Assessment; QUADAS (2) – Quality Assessment of Diagnostic Accuracy Studies
 472 (Version 2); RE – random effects; TDCPS – Torrance Developmental Classification of Pressure Sore.

473

474 Table 3. Results of reviews reporting model development and validation

Review author (publication year)	DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation methods	Brief description of study quality	Summary of model performance results
Barghouthi ⁵⁵ (2023)	DEV (23)	Setting of included studies NS, but the review's inclusion criteria specified hospital settings Retrospective n=15; prospective n=5; both retrospective and prospective n=1; case-control study n=1; experimental study design n=1 EHRs n=20; international or national database n=3	LR n=18; RF n=13; DT n=5; NN n=5; SVM n=5; Fine-Gray Model n=2; KNN n=2; XGBoost n=2; Adaboost n=1; BART n=1; EBM n=1; Gaussian Naïve Bayes n=1; GB n=1; GBM n=1; LDA n=1; NB n=1	Split sample n=17; NS n=6	RoB assessed using JBI critical appraisal checklist for cohort studies, and only summary results provided. Only one domain was low RoB across all included studies, which was whether the participants were free from the outcome (PIs) at the start of the study. Domains with mostly high-risk (<50%) or moderate-risk (51-81%) results related to statistical analysis methods, follow-up time, dealing with confounding factors, and measurement of the exposure.	Only reported measures of discrimination: Accuracy ranged between 0.52 (ML Walther ⁷³) and 0.99 (ML Anderson ⁷⁴); Sensitivity ranged between 0.04 (ML Walther ⁷³) and 1 (ML Hu ⁷⁵ , ML Anderson ⁷⁴); Specificity ranged between 0.69 (ML Hyun ⁷⁶ , ML Nakagami ⁷⁷) and 1 (ML Cai ⁷⁸ , ML Walther ⁷³); PPV ranged between 0.01 (ML Nakagami ⁷⁷) and 1 (ML Cai ⁷⁸); NPV ranged between 0.08 (ML SPURS ⁷⁹ , ML Cramer ⁸⁰) and 1 (ML Hu ⁷⁵ , ML Anderson ⁷⁴ , ML Ladios-Martin ⁸¹); AUC ranged between 0.50 (ML Cai ⁷⁸) and 1 (ML Hu ⁷⁵ , ML Cai ⁷⁸)
Dweekat ³⁶ (2023)	DEV (34); unclear (1) ^A	HAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2 Data sources NS	LR n=20; RF n=18; DT n=12; SVM n=12; MLP n=9; KNN n=4; LDA n=1; other n=19	CV n=10; split sample n=10; split sample and CV n=8; NS n=7	No RoB assessment	Results not reported; review focused on methods only
Jiang ³⁷ (2021)	DEV (9)	ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end-of-life care n=1; mobility-related disabilities n=1 EHRs used in all models	DT n=5; LR n=3; NN n=2; SVM n=2; BN n=1; GB n=1; MTS n=1; RF n=1	Split sample n=4; NS n=9	RoB assessed using PROBAST. Overall RoB high for all predictive models. All models at high RoB in analysis domain.	Only reported measures of discrimination: F-score ranged between 0.377 (ML Su MTS ⁸²) and 0.670 (ML Su LR ⁸²); G-means ranged between 0.628 (ML Kaewprag BN ⁸³) and 0.822 (ML Su MTS ⁸²); Sensitivity ranged between 0.478 (ML Kaewprag ⁸³) and 0.848 (ML Yang ⁸⁴); Specificity ranged between 0.703 (ML Deng ⁸⁵) and 0.988 (ML Su LR ⁸²)
Pei ⁵⁴ (2023)	DEV (17); DEV+VAL (1)	DEV ICU n=4; hospitalised patients n=8; hospitalised patients	RF n=12; LR n=11; DT n=9; SVM n=8; NN n=5; MTS n=1;	CV n=1; Split sample n=5; split sample and CV	RoB assessed using PROBAST. Overall, 16/18 (88.9%) papers were at high RoB, 1 (5.6%) was at	Only reported measures of discrimination: Summary AUC 0.9449

Review author (publication year)	DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation methods	Brief description of study quality	Summary of model performance results
		awaiting surgery n=3; cancer patients n=1; end-of-life inpatients n=1 Retrospective n=14; prospective n=3 EHRs n=12; MIMIC-IV database n=1; CONCERN database n=1 <i>DEV+VAL</i> ICU n=1 Retrospective n=1 EHRs n=1	NB n=3; KNN n=2; MLP n=1; XGBoost n=2; BART n=1; LASSO n=1; BN n=1; ANN n=1; EN n=1; GBM n=1; Other ^B n=1	n=10; NS n=2	unclear RoB and only 1 (5.6%) was at low RoB. 14 (77.8%) studies were at high RoB in the analysis domain. The most common factors contributing to the high risk of bias in the analysis domain included an inadequate number of events per candidate predictor, poor handling of missing data and failure to deal with overfitting.	<i>Summary sensitivity</i> 0.79 (95% CI: 0.78, 0.80); N _{cases} = 19,893 <i>Summary specificity</i> 0.87 (95% CI: 0.88, 0.87); N _{non-cases} = 388,611 <i>Summary likelihood ratios</i> PLR 10.71 (95% CI: 5.98, 19.19) NLR 0.21 (95% CI: 0.08, 0.50) <i>Pooled odds ratio</i> 52.39 (95% CI: 24.83, 110.55)
Ribeiro ⁵¹ (2021)	DEV (3)	SRPI cardiovascular n=2; SRPI critical care n=1 EHRs used in n=2 models	ANN n=1; RF n=1; XGBoost n=1	Split sample n=2; NS n=1	No RoB assessment	Only reported measures of discrimination: Accuracy ranged between 0.79 (ML Alderden ⁸⁶) and 0.82 (ML Chen ⁸⁷).
Shi ⁵² (2019)	DEV (21); VAL (7)	<i>DEV</i> General acute care hospital n=7; long-term care n=5; specific acute care (e.g. ICU) n=4; cardiovascular surgery n=2; trauma and burn centres n=1; rehabilitation units n=1; unclear n=1 Retrospective n=11; prospective n=10 <i>VAL</i> Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care) hospital n=2 Retrospective n=4; prospective n=3	LR n=16; cox regression n=5; ANN n=1; C4.5 ML (DT induction algorithm) n=1; DA n=1; DT n=1; NS n=1	CV n=1; tree-pruning n=1; split sample n=1; re-sampling n=2; NS n=16	RoB assessed using PROBAST. <i>DEV</i> Overall RoB unclear for two models. Overall RoB high for the remaining 19 models. Analysis and outcome domains were mostly at high RoB. <i>VAL</i> Overall RoB unclear for three validation studies. Overall RoB high for the remaining four validation studies. Analysis and outcome domains were mostly at high RoB.	C-statistics ^C ranged between 0.61 (interRAI PURS ⁸⁸) and 0.90 (TNH-PUPP ⁸⁹); O/E ratios ^C ranged between 0.91 (Berlowitz MDS ⁹⁰) and 1.0 (prePURSE study tool ⁹¹) <i>Pooled C-statistics^C</i> TNH-PUPP ⁸⁹ : 0.86 (95% CI 0.81–0.90), n=2 Fragmmnt scale ⁹² : 0.79 (95% CI 0.77–0.82), n=1 ^D Berlowitz 11-item model ⁹³ : 0.75 (95% CI 0.74–0.76), n=2 Berlowitz MDS model ⁹⁰ : 0.73 (95% CI 0.72–0.74), n=2 interRAI PURS ⁸⁸ : 0.65 (95% CI 0.60–0.69), n=3 Compton ⁹⁴ : 0.81 (95% CI 0.78–0.84), n=2 <i>Pooled O/E ratios^C</i> Berlowitz 11-item model ⁹³ : 0.99 (95% CI 0.95–1.04), n=2

Review author (publication year)	DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation methods	Brief description of study quality	Summary of model performance results
						Berlowitz MDS ⁹⁰ : 0.94 (95% CI 0.88–1.01), n=2
Zhou ⁵³ (2022)	DEV (22)	SRPI n=3; ICU n=11; hospitalised n=6; rehabilitation centre n=1; hospice n=1 EHR n=18; MIMIC-III database n=4	LR n=15; RF n=10; DT n=9; SVM n=9; ANN n=8; BN n=3; XGBoost n=3; GB n=2; AdaBoost n=1; CANTRIP n=1; LSTM n=1; EN n=1; KNN n=1; MTS n=1; NB n=1	CV n=12; NS n=10	RoB assessed using PROBAST. Overall RoB unclear for five studies. Overall RoB high for 15 models. RoB not assessed in two studies due to use of unstructured data.	Only reported measures of discrimination: F1 score ranged between 0.02 (ML Nakagami ⁷⁷) and 0.99 (ML Song [2] ⁹⁵); AUC ranged between 0.78 (ML Delparte ⁹⁶) and 0.99 (ML Song [2] ⁹⁵); Sensitivity ranged between 0.08 (ML Cai ⁷⁸) and 0.99 (ML Song [2] ⁹⁵); Specificity ranged between 0.63 (ML Delparte ⁹⁶) and 1 (ML Cai ⁷⁸)

475 ^A Appears to be a model validation study but the review only included model development studies.

476 ^B Other includes: average perception, Bayes point machine, boosted DT, boosted decision forest, decision jungle and locally deep SVM. All reported for one study⁸¹.

477 ^C Values from fixed-effects meta-analyses, pooling development and external validation study estimates together.

478 ^D One data source but included two C-statistic values (one for model development and one for internal validation) that were subsequently pooled.

479 AUC – area under curve; ANN – artificial neural network; BART – Bayesian additive regression tree; BN – Bayesian network; CAPI – community-acquired pressure injury; CANTRIP - reCurrent
480 Additive Network for Temporal Risk Prediction; CONCERN – Communicating Narrative Concerns Entered; CV – cross-validation; DEV – development; DOR – diagnostic odds ratio; DT – decision
481 tree; EBM – explainable boosting machine; EHRs – electronic health records; EN – elastic net; GB(M) – gradient boosting (machine); HAPI – hospital-acquired pressure injury; ICU – intensive
482 care unit; JBI – Joanna Briggs Institute; KNN – k-nearest neighbours; LASSO – least absolute shrinkage and selection operator; (L)DA – (linear) discriminant analysis; LSTM – long short-term
483 memory; LR – logistic regression; MIMIC – Medical Information Mart for Intensive Care; ML – machine learning; MLP – multilayer perceptron; MTS – Mahalanobis-Taguchi system; N/A – not
484 applicable; NB – naïve Bayes; NN – neural network; NLR – negative likelihood ratio; NS – not stated; O/E – observed vs expected; PI – pressure injury; PLR – positive likelihood ratio; PROBAST –
485 Prediction model Risk of Bias Assessment Tool; RF – random forest; RoB – risk of bias; SRPI – surgery-related pressure injury; SVM – support vector machine; VAL – validation; XGBoost –
486 extreme gradient boosting

487 Declarations

488 Ethics approval and consent to participate

489 Not applicable.

490 Consent for publication

491 Not applicable.

492 Availability of data and materials

493 All data produced in the present work are contained in the manuscript and supplementary file.

494 Conflicting Interests

495 The authors of this manuscript have the following competing interests: VV is an employee of Paul
496 Hartmann AG; ES and THB received consultancy fees from Paul Hartmann AG. VV, ES and THB were
497 not involved in data curation, screening, data extraction, analysis of results or writing of the original
498 draft. These roles were conducted independently by authors at the University of Birmingham. All
499 other authors received no personal funding or personal compensation from Paul Hartmann AG and
500 have declared that no competing interests exist.

501 Funding

502 This work was commissioned and supported by Paul Hartmann AG (Heidenheim, Germany), part of
503 HARTMANN GROUP. The contract with the University of Birmingham was agreed on the legal
504 understanding that the authors had the freedom to publish results regardless of the findings.

505 YT, JD, BH and AC are funded by the National Institute for Health and Care Research (NIHR)
506 Birmingham Biomedical Research Centre (BRC). This paper presents independent research supported
507 by the NIHR Birmingham BRC at the University Hospitals Birmingham NHS Foundation Trust and the
508 University of Birmingham. The views expressed are those of the authors and not necessarily those of
509 the NIHR or the Department of Health and Social Care.

510 Author Contributions

511 **Conceptualisation:** Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout
512 Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

513 **Data curation:** Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes

514 **Formal analysis:** Bethany Hillier, Katie Scandrett, Jacqueline Dinnes

515 **Funding acquisition:** Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

516 **Investigation:** Bethany Hillier, Katie Scandrett, April Coombe, Yemisi Takwoingi, Jacqueline Dinnes

517 **Methodology:** Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout
518 Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

519 **Project administration:** Bethany Hillier, Yemisi Takwoingi, Jacqueline Dinnes

520 **Resources:** Bethany Hillier, Katie Scandrett

521 **Supervision:** Yemisi Takwoingi, Jacqueline Dinnes

522 **Writing – original draft:** Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes

523 **Writing – review & editing:** Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard,
524 Ewout Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

525 **Acknowledgements**

526 We would like to thank Mrs. Rosie Boodell (University of Birmingham, UK) for her help in acquiring
527 the publications necessary to complete this piece of work.

References

- 528 1. Li Z, Lin F, Thalib L, et al. Global prevalence and incidence of pressure injuries in hospitalised adult
529 patients: A systematic review and meta-analysis. *International Journal of Nursing Studies*
530 2020;105:103-546. doi: 10.1016/j.ijnurstu.2020.103546
- 531 2. Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United
532 States. *Int Wound J* 2019;16(3):634-40. doi: 10.1111/iwj.13071 [published Online First:
533 2019/01/28]
- 534 3. Theisen S, Drabik A, Stock S. Pressure ulcers in older hospitalised patients and its impact on length
535 of stay: a retrospective observational study. *J Clin Nurs* 2012;21(3-4):380-7. doi:
536 10.1111/j.1365-2702.2011.03915.x [published Online First: 2011/12/09]
- 537 4. Sullivan N, Schoelles K. Preventing In-Facility Pressure Ulcers as a Patient Safety Strategy. *Annals of*
538 *Internal Medicine* 2013;158(5.2):410-16. doi: 10.7326/0003-4819-158-5-201303051-00008
- 539 5. Institute for Quality and Efficiency in Health Care (IQWiG). Preventing pressure ulcers. Cologne,
540 Germany 2006 [updated 2018 Nov 15. Available from:
541 <https://www.ncbi.nlm.nih.gov/books/NBK326430/?report=classic> accessed Feb 2023].
- 542 6. Haesler E. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and
543 Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries:
544 Clinical Practice Guideline. 2019 [Available from: <https://internationalguideline.com/2019>
545 accessed Feb 2023].
- 546 7. Walker RM, Gillespie BM, McInnes E, et al. Prevention and treatment of pressure injuries: A meta-
547 synthesis of Cochrane Reviews. *Journal of Tissue Viability* 2020;29(4):227-43. doi:
548 10.1016/j.jtv.2020.05.004
- 549 8. Shi C, Dumville JC, Cullum N, et al. Beds, overlays and mattresses for preventing and treating
550 pressure ulcers: an overview of Cochrane Reviews and network meta-analysis. *Cochrane*
551 *Database Syst Rev* 2021;8(8):Cd013761. doi: 10.1002/14651858.CD013761.pub2 [published
552 Online First: 2021/08/16]
- 553 9. Russo CA, Steiner C, Spector W. Hospitalizations Related to Pressure Ulcers, 2006. HCUP Statistical
554 Brief: Agency for Healthcare Research and Quality, Rockville, MD. 2008.
- 555 10. Braden B, Bergstrom N. A Conceptual Schema for the Study of the Etiology of Pressure Sores.
556 *Rehabilitation Nursing* 1987;12(1):8-16. doi: 10.1002/j.2048-7940.1987.tb00541.x
- 557 11. Bergstrom N, Braden BJ, Laguzza A, et al. The Braden Scale for Predicting Pressure Sore Risk. *Nurs*
558 *Res* 1987;36(4):205-10.
- 559 12. Norton D. Geriatric nursing problems. *Int Nurs Rev* 1962;9:39-41.
- 560 13. Waterlow J. Pressure sores: a risk assessment card. *Nursing Times* 1985;81:49-55.
- 561 14. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and
562 external validation. *J Clin Epidemiol* 2016;69:245-7. doi: 10.1016/j.jclinepi.2015.04.005
563 [published Online First: 2015/04/18]
- 564 15. Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3:
565 Prognostic Model Research. *PLOS Medicine* 2013;10(2):e1001381. doi:
566 10.1371/journal.pmed.1001381
- 567 16. Siontis GCM, Tzoulaki I, Castaldi PJ, et al. External validation of new risk prediction models is
568 infrequent and reveals worse prognostic discrimination. *Journal of Clinical Epidemiology*
569 2015;68(1):25-34. doi: 10.1016/j.jclinepi.2014.09.007
- 570 17. Bouwmeester W, Zuithoff NPA, Mallett S, et al. Reporting and Methods in Clinical Prediction
571 Research: A Systematic Review. *PLOS Medicine* 2012;9(5):e1001221. doi:
572 10.1371/journal.pmed.1001221
- 573 18. Van Calster B, Steyerberg EW, Wynants L, et al. There is no such thing as a validated prediction
574 model. *BMC Medicine* 2023;21(1):70. doi: 10.1186/s12916-023-02779-w

- 575 19. Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-
576 19: systematic review and critical appraisal. *BMJ* 2020;369:m1328. doi: 10.1136/bmj.m1328
- 577 20. Ma J, Dhiman P, Qi C, et al. Poor handling of continuous predictors in clinical prediction models
578 using logistic regression: a systematic review. *J Clin Epidemiol* 2023;161:140-51. doi:
579 10.1016/j.jclinepi.2023.07.017 [published Online First: 2023/08/02]
- 580 21. Dhiman P, Ma J, Qi C, et al. Sample size requirements are not being considered in studies
581 developing prediction models for binary outcomes: a systematic review. *BMC Medical*
582 *Research Methodology* 2023;23(1):188. doi: 10.1186/s12874-023-02008-1
- 583 22. Moriarty AS, Meader N, Snell KIE, et al. Predicting relapse or recurrence of depression: systematic
584 review of prognostic models. *Br J Psychiatry* 2022;221(2):448-58. doi: 10.1192/bjp.2021.218
- 585 23. Andaur Navarro CL, Damen JAA, Takada T, et al. Risk of bias in studies on prediction models
586 developed using supervised machine learning techniques: systematic review. *BMJ*
587 2021;375:n2281. doi: 10.1136/bmj.n2281
- 588 24. Christodoulou E, Ma J, Collins GS, et al. A systematic review shows no performance benefit of
589 machine learning over logistic regression for clinical prediction models. *J Clin Epidemiol*
590 2019;110:12-22. doi: 10.1016/j.jclinepi.2019.02.004 [published Online First: 20190211]
- 591 25. Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta-analysis of
592 prediction model performance. *BMJ* 2017;356:i6460. doi: 10.1136/bmj.i6460
- 593 26. Riley RD, van der Windt D, Croft P, et al. Prognosis research in healthcare: concepts, methods,
594 and impact: Oxford University Press 2019.
- 595 27. Snell KIE, Levis B, Damen JAA, et al. Transparent reporting of multivariable prediction models for
596 individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses
597 (TRIPOD-SRMA). *BMJ* 2023;381:e073538. doi: 10.1136/bmj-2022-073538
- 598 28. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability
599 of Prediction Model Studies. *Annals of Internal Medicine* 2019;170(1):51-58. doi:
600 10.7326/M18-1376
- 601 29. Chen HL, Shen WQ, Liu P. A Meta-analysis to Evaluate the Predictive Validity of the Braden Scale
602 for Pressure Ulcer Risk Assessment in Long-term Care. *Ostomy/wound management*
603 2016;62(9):20-8.
- 604 30. Baris N, Karabacak BG, Alpar SE. The Use of the Braden Scale in Assessing Pressure Ulcers in
605 Turkey: A Systematic Review. *Advances in skin & wound care* 2015;28:349-57. doi:
606 10.1097/01.ASW.0000465299.99194.e6
- 607 31. He W, Liu P, Chen HL. The Braden Scale cannot be used alone for assessing pressure ulcer risk in
608 surgical patients: a meta-analysis. *Ostomy/wound management* 2012;58:34-40.
- 609 32. Huang C, Ma Y, Wang C, et al. Predictive validity of the braden scale for pressure injury risk
610 assessment in adults: A systematic review and meta-analysis. *Nursing open* 2021;8:2194-207.
611 doi: 10.1002/nop2.792
- 612 33. Park SH, Choi YK, Kang CB. Predictive validity of the Braden Scale for pressure ulcer risk in
613 hospitalized patients. *Journal of Tissue Viability* 2015;24:102-13. doi:
614 10.1016/j.jtv.2015.05.001
- 615 34. Wei M, Wu L, Chen Y, et al. Predictive Validity of the Braden Scale for Pressure Ulcer Risk in
616 Critical Care: A Meta-Analysis. *Nursing in critical care* 2020;25:165-70. doi:
617 10.1111/nicc.12500
- 618 35. Wilchesky M, Lungu O. Predictive and concurrent validity of the Braden scale in long-term care: A
619 meta-analysis. *Wound Repair and Regeneration* 2015;23:44-56. doi: 10.1111/wrr.12261
- 620 36. Dweekat OY, Lam SS, McGrath L. Machine Learning Techniques, Applications, and Potential Future
621 Opportunities in Pressure Injuries (Bedsore) Management: A Systematic Review.
622 *International journal of environmental research and public health* 2023;20(1) doi:
623 10.3390/ijerph20010796
- 624 37. Jiang M, Ma Y, Guo S, et al. Using Machine Learning Technologies in Pressure Injury Management:
625 Systematic Review. *JMIR Medical Informatics* 2021;9(3):e25704. doi: 10.2196/25704

- 626 38. Qu C, Luo W, Zeng Z, et al. The predictive effect of different machine learning algorithms for
627 pressure injuries in hospitalized patients: A network meta-analyses. *Heliyon*
628 2022;8(11):e11361. doi: 10.1016/j.heliyon.2022.e11361
- 629 39. Hillier B, Scandrett K, Coombe A, et al. Accuracy and clinical effectiveness of risk prediction tools
630 for pressure injury occurrence: An umbrella review (pre-print). *MedRxiv* 2024 doi:
631 10.1101/2024.05.07.24307001
- 632 40. Pollock M, Fernandes RM BL, Pieper D, Hartling L, Chapter V: Overviews of Reviews. In: Higgins
633 JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA ed. *Cochrane Handbook for*
634 *Systematic Reviews of Interventions* version 63 (updated February 2022). Available from
635 www.training.cochrane.org/handbook: Cochrane 2022.
- 636 41. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-
637 Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi:
638 10.1371/journal.pmed.1000097
- 639 42. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. *J Am Med Inform Assoc*
640 2001;8(4):391-7. doi: 10.1136/jamia.2001.0080391 [published Online First: 2001/06/22]
- 641 43. Wilczynski NL, Haynes RB. Optimal Search Strategies for Detecting Clinically Sound Prognostic
642 Studies in EMBASE: An Analytic Survey. *Journal of the American Medical Informatics*
643 *Association* 2005;12(4):481-85. doi: 10.1197/jamia.M1752
- 644 44. Geersing G-J, Bouwmeester W, Zuithoff P, et al. Search Filters for Finding Prognostic and
645 Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews. *PLOS ONE*
646 2012;7(2):e32844. doi: 10.1371/journal.pone.0032844
- 647 45. NHS. Pressure ulcers: revised definition and measurement. Summary and recommendations 2018
648 [Available from: [https://www.england.nhs.uk/wp-content/uploads/2021/09/NSTPP-](https://www.england.nhs.uk/wp-content/uploads/2021/09/NSTPP-summary-recommendations.pdf)
649 [summary-recommendations.pdf](https://www.england.nhs.uk/wp-content/uploads/2021/09/NSTPP-summary-recommendations.pdf) accessed Feb 2023].
- 650 46. AHCPR. Pressure ulcer treatment. : Agency for Health Care Policy and Research 1994:1-25.
- 651 47. Harker J. Pressure ulcer classification: the Torrance system. *Journal of Wound Care* 2000;9(6):275-
652 77. doi: 10.12968/jowc.2000.9.6.26233
- 653 48. Moons KGM, de Groot JAH, Bouwmeester W, et al. Critical Appraisal and Data Extraction for
654 Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. *PLOS Medicine*
655 2014;11(10):e1001744. doi: 10.1371/journal.pmed.1001744
- 656 49. Cochrane. DE form example prognostic models - scoping review: The Cochrane Collaboration: The
657 Prognosis Methods Group; [Available from: <https://methods.cochrane.org/prognosis/tools>
658 accessed Feb 2023].
- 659 50. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that
660 include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*
661 2017;358:j4008. doi: 10.1136/bmj.j4008
- 662 51. Ribeiro F, Fidalgo F, Silva A, et al. Literature review of machine-learning algorithms for pressure
663 ulcer prevention: Challenges and opportunities: MDPI 2021.
- 664 52. Shi C, Dumville JC, Cullum N. Evaluating the development and validation of empirically-derived
665 prognostic models for pressure ulcer risk assessment: A systematic review. *International*
666 *journal of nursing studies* 2019;89:88-103. doi: 10.1016/j.ijnurstu.2018.08.005
- 667 53. Zhou Y, Yang X, Ma S, et al. A systematic review of predictive models for hospital-acquired
668 pressure injury using machine learning. *Nursing open* 2022;30 doi: 10.1002/nop2.1429
- 669 54. Pei J, Guo X, Tao H, et al. Machine learning-based prediction models for pressure injury: A
670 systematic review and meta-analysis. *Int Wound J* 2023 doi: 10.1111/iwj.14280 [published
671 Online First: 2023/06/20]
- 672 55. Barghouthi EaD, Owda AY, Asia M, et al. Systematic Review for Risks of Pressure Injury and
673 Prediction Models Using Machine Learning Algorithms. *Diagnostics (Basel, Switzerland)*
674 2023;13(17) doi: 10.3390/diagnostics13172739
- 675 56. Chou R, Dana T, Bougatsos C, et al. Pressure ulcer risk assessment and prevention: a systematic
676 comparative effectiveness review. *Annals of internal medicine* 2013;159(1):28-38.

- 677 57. García-Fernández FP, Pancorbo-Hidalgo PL, Agreda JJS. Predictive Capacity of Risk Assessment
678 Scales and Clinical Judgment for Pressure Ulcers: A Meta-analysis. *Journal of Wound Ostomy*
679 *& Continence Nursing* 2014;41(1):24-34. doi: 10.1097/01.WON.0000438014.90734.a2
680 58. Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Lopez-Medina IM, et al. Risk assessment scales for
681 pressure ulcer prevention: a systematic review. *J Adv Nurs* 2006;54(1):94-110. doi:
682 10.1111/j.1365-2648.2006.03794.x
683 59. Park SH, Lee HS. Assessing Predictive Validity of Pressure Ulcer Risk Scales- A Systematic Review
684 and Meta-Analysis. *Iranian journal of public health* 2016;45(2):122-33.
685 60. Park SH, Lee YS, Kwon YM. Predictive Validity of Pressure Ulcer Risk Assessment Tools for Elderly:
686 A Meta-Analysis. *Western journal of nursing research* 2016;38:459-83. doi:
687 10.1177/0193945915602259
688 61. Tayyib NAH, Coyer F, Lewis P. Pressure ulcers in the adult intensive care unit: a literature review of
689 patient risk factors and risk assessment scales. *Journal of Nursing Education and Practice*
690 2013;3(11):28-42.
691 62. Wang N, Lv L, Yan F, et al. Biomarkers for the early detection of pressure injury: A systematic
692 review and meta-analysis. *Journal of Tissue Viability* 2022;31:259-67. doi:
693 10.1016/j.jtv.2022.02.005
694 63. Zhang Y, Zhuang Y, Shen J, et al. Value of pressure injury assessment scales for patients in the
695 intensive care unit: Systematic review and diagnostic test accuracy meta-analysis. *Intensive &*
696 *critical care nursing* 2021;64:103009. doi: 10.1016/j.iccn.2020.103009
697 64. Zimmermann GS, Cremasco MF, Zanei SSV, et al. Pressure injury risk prediction in critical care
698 patients: an integrative review. *Texto & Contexto-Enfermagem* 2018;27(3)
699 65. Chen X, Diao D, Ye L. Predictive validity of the Jackson-Cubbin scale for pressure ulcers in
700 intensive care unit patients: A meta - analysis. *Nursing in Critical Care* 2023;28(3):370-78.
701 doi: 10.1111/nicc.12818
702 66. Mehicic A, Burston A, Fulbrook P. Psychometric properties of the Braden scale to assess pressure
703 injury risk in intensive care: A systematic review. *Intensive & critical care nursing*
704 2024;83:103686. doi: 10.1016/j.iccn.2024.103686
705 67. Gaspar S, Peralta M, Marques A, et al. Effectiveness on hospital-acquired pressure ulcers
706 prevention: a systematic review. *International Wound Journal* 2019;16(5):1087-102. doi:
707 10.1111/iwj.13147
708 68. Ontario HQ. Pressure ulcer prevention: an evidence-based analysis. *Ontario health technology*
709 *assessment series* 2009;9(2):1-104.
710 69. Kottner J, Dassen T, Tannen A. Inter- and intrarater reliability of the Waterlow pressure sore risk
711 scale: A systematic review. *International Journal of Nursing Studies* 2009;46:369-79. doi:
712 10.1016/j.ijnurstu.2008.09.010
713 70. Lovegrove J, Ven S, Miles SJ, et al. Comparison of pressure injury risk assessment outcomes using
714 a structured assessment tool versus clinical judgement: A systematic review. *Journal of*
715 *Clinical Nursing* 2021 doi: 10.1111/jocn.16154 [published Online First: 2021/12/01]
716 71. Lovegrove J, Miles S, Fulbrook P. The relationship between pressure ulcer risk assessment and
717 preventative interventions: a systematic review. *Journal of wound care* 2018;27(12):862-75.
718 72. Moore ZEH, Patton D. Risk assessment tools for the prevention of pressure ulcers. *Cochrane*
719 *Database of Systematic Reviews* 2019 doi: 10.1002/14651858.CD006471.pub4
720 73. Walther F, Heinrich L, Schmitt J, et al. Prediction of inpatient pressure ulcers based on routine
721 healthcare data using machine learning methodology. *Scientific Reports* 2022;12(1):5044.
722 74. Anderson C, Bekele Z, Qiu Y, et al. Modeling and prediction of pressure injury in hospitalized
723 patients using artificial intelligence. *BMC Med Inform Decis Mak* 2021;21(1):253. doi:
724 10.1186/s12911-021-01608-5 [published Online First: 20210830]
725 75. Hu YH, Lee YL, Kang MF, et al. Constructing Inpatient Pressure Injury Prediction Models Using
726 Machine Learning Techniques. *Cin-Computers Informatics Nursing* 2020;38(8):415-23. doi:
727 10.1097/cin.0000000000000604

- 728 76. Hyun S, Moffatt-Bruce S, Cooper C, et al. Prediction Model for Hospital-Acquired Pressure Ulcer
729 Development: Retrospective Cohort Study. *Jmir Medical Informatics* 2019;7(3) doi:
730 10.2196/13785
- 731 77. Nakagami G, Yokota S, Kitamura A, et al. Supervised machine learning-based prediction for in-
732 hospital pressure injury development using electronic health records: A retrospective
733 observational cohort study in a university hospital in Japan. *International Journal of Nursing*
734 *Studies* 2021;119 doi: 10.1016/j.ijnurstu.2021.103932
- 735 78. Cai JY, Zha ML, Song YP, et al. Predicting the Development of Surgery-Related Pressure Injury
736 Using a Machine Learning Algorithm Model. *Journal of Nursing Research* 2021;29(1) doi:
737 10.1097/jnr.0000000000000411
- 738 79. Aloweni F, Ang SY, Fook-Chong S, et al. A prediction tool for hospital-acquired pressure ulcers
739 among surgical patients: Surgical pressure ulcer risk score. *Int Wound J* 2019;16(1):164-75.
740 doi: 10.1111/iwj.13007 [published Online First: 2018/10/05]
- 741 80. Cramer EM, Seneviratne MG, Sharifi H, et al. Predicting the Incidence of Pressure Ulcers in the
742 Intensive Care Unit Using Machine Learning. *EGEMS (Wash DC)* 2019;7(1):49. doi:
743 10.5334/egems.307 [published Online First: 20190905]
- 744 81. Ladios-Martin M, Fernández-de-Maya J, Ballesta-López FJ, et al. Predictive Modeling of Pressure
745 Injury Risk in Patients Admitted to an Intensive Care Unit. *Am J Crit Care* 2020;29(4):e70-e80.
746 doi: 10.4037/ajcc2020237
- 747 82. Su CT, Wang PC, Chen YC, et al. Data Mining Techniques for Assisting the Diagnosis of Pressure
748 Ulcer Development in Surgical Patients. *Journal of Medical Systems* 2012;36(4):2387-99. doi:
749 10.1007/s10916-011-9706-1
- 750 83. Kaewprag P, Newton C, Vermillion B, et al. Predictive models for pressure ulcers from intensive
751 care unit electronic health records using Bayesian networks. *Bmc Medical Informatics and*
752 *Decision Making* 2017;17 doi: 10.1186/s12911-017-0471-z
- 753 84. Yang Q, Wang G, Jiang B, et al. Study on risk prediction model of unavoidable pressure ulcers in
754 cancer patients based on decision tree. *Journal of Nursing Science* 2019;34(13):4-7.
- 755 85. Deng X, Wang Q, Li M, et al. Predicting the risk of hospital-acquired pressure ulcers in intensive
756 care unit patients based on decision tree. *Chin J Prac Nurs* 2016;32:485-89.
- 757 86. Alderden J, Pepper GA, Wilson A, et al. Predicting Pressure Injury in Critical Care Patients: A
758 Machine-Learning Model. *Am J Crit Care* 2018;27(6):461-68. doi: 10.4037/ajcc2018525
- 759 87. Chen HL, Yu SJ, Xu Y, et al. Artificial Neural Network: A Method for Prediction of Surgery-Related
760 Pressure Injury in Cardiovascular Surgical Patients. *Journal of Wound Ostomy and Continence*
761 *Nursing* 2018;45(1):26-30. doi: 10.1097/won.0000000000000388
- 762 88. Poss J, Murphy KM, Woodbury MG, et al. Development of the interRAI Pressure Ulcer Risk Scale
763 (PURS) for use in long-term care and home care settings. *BMC geriatrics* 2010;10:67. doi:
764 10.1186/1471-2318-10-67
- 765 89. Page KN, Barker AL, Kamar J. Development and validation of a pressure ulcer risk assessment tool
766 for acute hospital patients. *Wound Repair and Regeneration* 2011;19(1):31-37. doi:
767 10.1111/j.1524-475X.2010.00647.x
- 768 90. Berlowitz DR, Brandeis GH, Morris JN, et al. Deriving a risk-adjustment model for pressure ulcer
769 development using the Minimum Data Set. *Journal of the American Geriatrics Society*
770 2001;49(7):866-71. doi: 10.1046/j.1532-5415.2001.49175.x
- 771 91. Schoonhoven L, Grobbee DE, Donders ART, et al. Prediction of pressure ulcer development in
772 hospitalized patients: a tool for risk assessment. *Quality & Safety in Health Care*
773 2006;15(1):65-70. doi: 10.1136/qshc.2005.015362
- 774 92. Perneger TV, Raë AC, Gaspoz JM, et al. Screening for pressure ulcer risk in an acute care hospital:
775 development of a brief bedside scale. *J Clin Epidemiol* 2002;55(5):498-504. doi:
776 10.1016/s0895-4356(01)00514-5

- 777 93. Berlowitz DR, Ash AS, Brandeis GH, et al. Rating long-term care facilities on pressure ulcer
778 development: importance of case-mix adjustment. *Annals of Internal Medicine*
779 1996;124(6):557-63.
- 780 94. Compton F, Hoffmann F, Hortig T, et al. Pressure ulcer predictors in ICU patients: nursing skin
781 assessment versus objective parameters. *J Wound Care* 2008;17(10):417-20, 22-4. doi:
782 10.12968/jowc.2008.17.10.31304
- 783 95. Song WY, Kang MJ, Zhang LY, et al. Predicting pressure injury using nursing assessment
784 phenotypes and machine learning methods. *Journal of the American Medical Informatics*
785 *Association* 2021;28(4):759-65. doi: 10.1093/jamia/ocaa336
- 786 96. Delparte JJ, Flett HM, Scovil CY, et al. Development of the spinal cord injury pressure sore onset
787 risk screening (SCI-PreSORS) instrument: a pressure injury risk decision tree for spinal cord
788 injury rehabilitation. *Spinal Cord* 2021;59(2):123-31. doi: 10.1038/s41393-020-0510-y
- 789 97. Cubbin B, Jackson C. Trial of a pressure area risk calculator for intensive therapy patients.
790 *Intensive Care Nursing* 1991;7(1):40-44.
- 791 98. Jackson C. The revised Jackson/Cubbin Pressure Area Risk Calculator. *Intensive Crit Care Nurs*
792 1999;15(3):169-75. doi: 10.1016/s0964-3397(99)80048-2
- 793 99. Berlowitz DR, Ash AS, Brandeis GH, et al. Rating long-term care facilities on pressure ulcer
794 development: Importance of case-mix adjustment. *Annals of Internal Medicine*
795 1996;124(6):557-63. doi: 10.7326/0003-4819-124-6-199603150-00003
- 796 100. Suriadi Sanada H, Sugama J, Thigpen B, et al. Development of a new risk assessment scale for
797 predicting pressure ulcers in an intensive care unit. *Nursing in critical care* 2008;13(1):34-43.
- 798 101. Lowery MT. A pressure sore risk calculator for intensive care patients: 'the Sunderland
799 experience'. *Intensive Crit Care Nurs* 1995;11(6):344-53. doi: 10.1016/s0964-3397(95)80452-
800 8
- 801 102. Sprigle S, McNair D, Sonenblum S. Pressure Ulcer Risk Factors in Persons with Mobility-Related
802 Disabilities. *Adv Skin Wound Care* 2020;33(3):146-54. doi:
803 10.1097/01.ASW.0000653152.36482.7d
- 804 103. Do Q, Lipatov K, Ramar K, et al. Pressure Injury Prediction Model Using Advanced Analytics for
805 At-Risk Hospitalized Patients. *Journal of patient safety* 2022;18(7):e1083-e89.
- 806 104. McCreath HE, Bates-Jensen BM, Nakagami G, et al. Use of Munsell color charts to measure skin
807 tone objectively in nursing home residents at risk for pressure ulcer development. *Journal of*
808 *Advanced Nursing* 2016;72(9):2077-85. doi: 10.1111/jan.12974
- 809 105. Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of different
810 strategies for estimating the out-of-sample validity of logistic regression models. *Stat*
811 *Methods Med Res* 2017;26(2):796-808. doi: 10.1177/0962280214558972 [published Online
812 First: 2014/11/19]
- 813 106. Smith GC, Seaman SR, Wood AM, et al. Correcting for optimistic prediction in small data sets.
814 *Am J Epidemiol* 2014;180(3):318-24. doi: 10.1093/aje/kwu140 [published Online First:
815 2014/06/24]
- 816 107. Riley RD, Collins GS. Stability of clinical prediction models developed using statistical or machine
817 learning methods. *Biometrical Journal* 2023;65(8):2200302. doi: 10.1002/bimj.202200302
- 818 108. Salazar D, Vélez J, Salazar Uribe J. Comparison between SVM and Logistic Regression: Which One
819 is Better to Discriminate? *Revista Colombiana de Estadística* 2012;35:223-37.
- 820 109. Ramspek CL, Jager KJ, Dekker FW, et al. External validation of prognostic models: what, why,
821 how, when and where? *Clin Kidney J* 2021;14(1):49-58. doi: 10.1093/ckj/sfaa188 [published
822 Online First: 2020/11/24]
- 823 110. de Hond AAH, Shah VB, Kant IMJ, et al. Perspectives on validation of clinical predictive
824 algorithms. *npj Digital Medicine* 2023;6(1):86. doi: 10.1038/s41746-023-00832-9
- 825 111. Binuya MAE, Engelhardt EG, Schats W, et al. Methodological guidance for the evaluation and
826 updating of clinical prediction models: a systematic review. *BMC Med Res Methodol*
827 2022;22(1):316. doi: 10.1186/s12874-022-01801-8 [published Online First: 2022/12/12]

- 828 112. Riley RD, Archer L, Snell KIE, et al. Evaluation of clinical prediction models (part 2): how to
829 undertake an external validation study. *BMJ* 2024;384:e074820. doi: 10.1136/bmj-2023-
830 074820
- 831 113. Hingorani AD, Windt DAVd, Riley RD, et al. Prognosis research strategy (PROGRESS) 4: Stratified
832 medicine research. *BMJ : British Medical Journal* 2013;346:e5793. doi: 10.1136/bmj.e5793
- 833 114. Qaseem A, Mir TP, Starkey M, et al. Risk Assessment and Prevention of Pressure Ulcers: A
834 Clinical Practice Guideline From the American College of Physicians. *Annals of Internal
835 Medicine* 2015;162(5):359-69. doi: 10.7326/m14-1567
- 836 115. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for
837 reporting diagnostic accuracy studies. *BMJ* 2015;351:h5527. doi: 10.1136/bmj.h5527
838 [published Online First: 2015/10/28]
- 839 116. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction
840 model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann
841 Intern Med* 2015;162(1):W1-73. doi: 10.7326/m14-0698
- 842 117. Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, et al. MINIMAR (MINimum Information for
843 Medical AI Reporting): Developing reporting standards for artificial intelligence in health
844 care. *Journal of the American Medical Informatics Association* 2020;27(12):2011-15. doi:
845 10.1093/jamia/ocaa088
- 846 118. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting
847 clinical prediction models that use regression or machine learning methods. *BMJ*
848 2024;385:e078378. doi: 10.1136/bmj-2023-078378